Alvimopan, a selective peripherally acting μ-opioid antagonist

Research output: Contribution to journalReview articlepeer-review

65 Scopus citations


Alvimopan is a novel, peripherally acting μ-opioid antagonist that is being developed for the management of acute postoperative ileus and for the reversal of the delayed gastrointestinal and colonic transit that result in symptoms such as constipation, nausea and motility disorders in patients treated with opiate analgesics. There is a clinical need for effective medications for the treatment of postoperative ileus and opiate-induced constipation and other motility disorders. This review addresses the basic and applied pharmacology and current evidence for the use of the medication, alvimopan, in clinical gastroenterology.

Original languageEnglish (US)
Pages (from-to)157-165
Number of pages9
JournalNeurogastroenterology and Motility
Issue number2
StatePublished - Apr 2005


  • Constipation
  • Gastrointestinal transit
  • Ileus
  • Irritable bowel

ASJC Scopus subject areas

  • Physiology
  • Endocrine and Autonomic Systems
  • Gastroenterology


Dive into the research topics of 'Alvimopan, a selective peripherally acting μ-opioid antagonist'. Together they form a unique fingerprint.

Cite this